LD-2020

N/A

Report date: 2023/12/08 15:06:09
NME

Base Information

Drug NameLD-2020
Drug Alias NameLD-2020
ClassificationSmall molecules
Mechanisms of ActionTransient receptor potential cation channel subfamily A member 1 inhibitors
TargetsTransient receptor potential cation channel subfamily A member 1
Therapy Area/IndicationsCancer PainPainOsteoarthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Lidao Medical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Lidao Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsCancer PainPainOsteoarthritis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A